EphB1 as a Novel Drug Target to Combat Pain and Addiction
Technical Report,01 Sep 2015,31 Aug 2016
University of Texas Southwestern Medical Center Dallas United States
Pagination or Media Count:
We have shown that the synaptic receptor protein known as EphB1 is a central player in nerve injury-induced neuropathic pain and the related pain symptoms associated with the withdrawal from opioidmorphine addiction. Our hypothesis is that postsynaptic EphB1 participates in pain through the ability of its extracellular domain to form protein-protein interactions with its presynaptic ligand, ephrin-B2, and the NR1 subunit of the postsynaptic NMDA receptor to inappropriately strengthen the synapses in the spinal cord that transmit pain signals into the brain. Our project is to carry out high-throughput screens HTS to identify small molecular weight drug-like compounds from a200,000 complex library that antagonize EphB1 protein-protein interactions. While we originally set out to target the EphB1NR1 protein-protein interaction, we changed directions in Year 2 due to technical difficulties and are now focusing on the interaction of EphB1 with ephrin-B2. We have made good progress in developing HTS for antagonists that disrupt the EphB1ephrin-B2 interaction and already have a small number of potential lead compounds from the initial pilot test screen of an 8,000 compound subset of the main library.
- Medicine and Medical Research